Almonty Industries

Phase A — Understand the business

Company Overview

Almonty Industries is a pure-play tungsten miner — one of the very few scaled producers of tungsten concentrate outside China — pivoting from a small, cash-generative European operator into the anchor Western-aligned tungsten supplier just as China weaponises the supply chain.

What it actually does: mines and processes scheelite/wolframite ore into tungsten concentrate (APT-grade WO₃), sold to downstream converters who turn it into ammonium paratungstate (APT) and tungsten metal/carbide. Tungsten's pitch is physical: highest melting point of any element (3,422°C), extreme hardness — irreplaceable in cutting tools, armour-piercing munitions, aerospace, and semiconductors ``.

Assets (the portfolio):

• Panasqueira (Portugal) — the legacy cash engine. ~126 years of near-continuous operation, fifth-generation miners; Portugal's largest tungsten operation. This is the entire revenue base today ``.
• Sangdong (South Korea) — the thesis. One of the world's largest, highest-grade tungsten deposits; restarted March 2026 after a ~30-year hiatus. Phase 1 ~2,300 t concentrate/yr; Phase 2 (2027) doubles to ~4,600 t/yr ``.
• Los Santos (Spain) — early/legacy asset (largely depleted/care).
• Valtreixal (Spain) — tungsten-tin development project.
• Gentung / Montana (USA) — recently acquired U.S. tungsten beachhead, "expected to restart production this year" ``.

Customers & contract structure (the de-risking): Sangdong is pre-sold under long-dated, hard-floor offtakes —

• 15-year tungsten offtake with Global Tungsten & Powders (a Plansee Group company), floor US$183/MTU WO₃ (≈ US$235/mtu APT-equivalent), no upside cap ``.
• Molybdenum offtake with SeAH M&S (Korea's largest moly processor) — 100% of Sangdong's moly at a US$19.00/lb floor ``.
• U.S. defense tungsten-oxide offtake + a partnership with American Defense International for direct access to U.S. defense primes ``.

The contract architecture is the single most important structural fact: it converts a commodity ramp into something closer to a floored, uncapped annuity — downside protected, full upside retained. (See Lens 3.)

Supply Chain

Map, named stakeholders upstream → Almonty → end use:

Upstream (inputs): conventional underground-mining inputs — no exotic single-source dependency on the input side. The binding constraint for Sangdong was capital and permitting, not feedstock. Project finance came partly from KfW IPEX-Bank (German export credit) — a US$75.1M facility tied to the Plansee/GTP offtake condition precedent ``. So the German industrial complex (Plansee + KfW + Deutsche Rohstoff as shareholder) effectively underwrote the Korean mine.

The company (conversion stage): mine ore → flotation → tungsten concentrate. Sangdong's scheelite mineralisation matters here: scheelite responds better to flotation than the wolframite that dominates Chinese supply, yielding higher-purity concentrate . Phase 2 adds an on-site **tungsten-oxide facility** + the adjacent **Sangdong molybdenum** deposit — the "**Korean Trinity**" integrated value chain .

Downstream (named buyers / chokepoint):

• Global Tungsten & Powders / Plansee Group (Austria/USA) — the converter that turns concentrate into APT and tungsten powder; also a top-5 Almonty shareholder (vertical alignment, not arm's-length).
• SeAH M&S (South Korea) — molybdenum oxide.
• U.S. Department of Defense / defense primes — via the tungsten-oxide offtake + American Defense International.
• End markets: cutting tools/carbide, defense munitions, aerospace, semiconductors (a fresh demand leg in 2025–26).

Chokepoints: Almonty's role is the chokepoint relief — the entire investment case is that China controls >80% of mined+processed tungsten and has restricted exports (Lens 3). Almonty's own concentration risk is the mirror image: single-mine dependence on Sangdong for the growth case (Panasqueira is mature), and downstream converter concentration in GTP/Plansee (though the floor offtake makes that a feature, not a bug, for now).

Competitive Advantages (moats)

The moat is geological + geopolitical + contractual, stacked — and unusually durable for a miner.

1. Geology (cost + quality moat). Sangdong: ~7.9 Mt P&P reserves, >45-year mine life, ~0.51% WO₃ grade (~3× the global average) ``. High grade + scheelite flotation = structurally low unit costs and premium concentrate. A 45-year reserve life is a multi-decade annuity, not a typical junior-miner story. (Note: AISC not disclosed in public sources — n/a; the grade implies low-cost-quartile but this is unconfirmed.)

2. Geopolitical exclusivity (the regulatory moat). Tungsten is on every Western critical-minerals list. From 1 Jan 2027 the Pentagon bans Chinese tungsten from military procurement ``. Almonty is the only scaled, Western-aligned, allied-jurisdiction producer ramping into that ban. Korea is a U.S. treaty ally; the U.S. domestication (Delaware) + Montana asset deepen the "American supply" framing. This is a moat the market is paying for — a non-Chinese tonne of tungsten under a defense-qualified offtake has scarcity value China cannot compete away.

3. Contractual moat (floored, uncapped). The 15-yr GTP floor at US$183/MTU with no cap, plus the SeAH moly floor, means Almonty captures the spike while a buyer absorbs the downside — rare risk asymmetry for a commodity producer ``.

4. Operator track record (process moat). 126 years at Panasqueira = institutional tungsten-mining know-how (fifth-generation miners). Restarting a 30-year-dormant mine on plan is itself a barrier — most juniors fail at exactly this step.

Bargaining power: asymmetrically strong right now — China's export squeeze means ex-China tungsten is scarce and buyers (defense, Plansee) need Almonty more than Almonty needs any single buyer. That power is cyclical, not permanent: it inverts the day China re-opens the taps or a price bust arrives (Lens 13).

Segments

our figures is empty ``; segmentation is reconstructed from web.

Geography: today Portugal-centric; pivoting to a Korea-centric revenue base from 2026–27, with U.S. (Montana) optionality. The segment story is a single sentence: a mature European cash cow funding/bridging to a high-grade Korean growth engine, mid-transition.

---

Phase B — Measure performance

Earnings Result (latest: Q1 2026, reported 2026-05-11)

• Revenue: C$25.4M, +221% YoY (from C$7.9M) ``. (Several outlets render this "$25.4M"; treat as CAD.)
• Adjusted EBITDA: +C$6.1M — turned positive ``.
• Operating cash flow: +C$9.7M vs −C$4.4M in Q1'25 — the inflection the bulls wanted ``.
• Driver: price, not volume. Panasqueira production −14.7% / shipments −15.5% YoY, fully overridden by APT pricing ``.
• Balance sheet: cash C$259.9M, working capital C$169.5M (31 Mar 2026) — before the June US$700M convertible ``.
• Market reaction: shares fell on the print despite +221% — investors fixated on Sangdong ramp execution, not Panasqueira's price-driven beat ``. Tell: the stock now trades on forward Sangdong delivery, so a backward-looking revenue beat doesn't move it.

FY2025 (reported 2026-03-18): headline net loss C$161.9M vs C$16.3M loss prior year — but C$87.3M of that is a non-cash loss on revaluation of embedded-derivative liabilities driven by the share-price appreciation during 2025 ``. Read carefully: a large chunk of the "loss" exists because the stock went up (convertible/derivative mark-to-market). Excluding it, Panasqueira delivered steady price-led growth and the company exited 2025 with >C$268M cash. This is the single most mis-read number on the company (see Lens 10).

Earnings Calls (sentiment trend)

No transcripts on disk ; sentiment from public commentary + shareholder letters .

• Management focus (consistent, escalating): "secure, reliable, geopolitically aligned supply of tungsten for the U.S. and its allies"; Sangdong commissioning → ramp → Phase 2; the "Korean Trinity"; the U.S. domestication + Montana "American supply" thread ``.
• Tone shift: from project-developer language (2024: "under construction", milestones, financing) → operator/strategic-supplier language (2026: "commercial operation", "cash flows are coming", positioning vs the 2027 Pentagon ban). CEO Lewis Black is overtly promotional and geopolitically framed (keynotes, "world's most advanced tungsten mine", CMI Summit warnings on a critical-minerals talent crisis) — high-conviction founder voice; weigh accordingly (Lens 9/13).
• What they stopped saying: construction-risk hedging; the narrative has hardened into "the supply shock validated us."

Comps

Tungsten is a thin, mostly-private/Chinese peer set — clean public comparables barely exist, which is itself part of the bull case (scarcity of the exposure).

Stock-Price Catalysts (moves >5%, last ~12–18 mo)

The tape reveals what the market actually trades: China policy + Sangdong execution + defense demand, in that order. High beta throughout.

• 2025 (China export controls, Feb onward) → tungsten +550%; Almonty ~$1 → ~$22–24 (~2,000%+) ``.
• Jul 2025: Nasdaq listing + US$90M oversubscribed offering at US$4.50 ``.
• Dec 2025: US$129M follow-on; Sangdong active mining begins ``.
• 15 Mar 2026: −8% — pullback on the first Sangdong production figures + vote to double output (classic "sell the milestone") ``.
• Episodic −5% to −8% premarket pullbacks on tungsten-price wobbles / "China easing" fears (e.g. shares to $20.75, $19.30) ``.
• May 2026: Q1 +221% revenue → shares still slid (forward-execution focus) ``.
• Jun 2026: US$700M convertible priced (settle 9 Jun); price ~$18.81 (19 Jun) off the ~$22–24 highs ``.

Pattern read: this is a commodity-policy proxy with execution overlay. It rips on China tightening / price, and corrects on "China easing" headlines and on good-news milestones (profit-taking). Earnings beats matter less than the tungsten print and Sangdong tonnes. Expect ±8% days to remain normal.

---

Phase C — Judge people & books

Management

Lewis Black — Founder & CEO. Founded Almonty 2011; tungsten lifer — ran Primary Metals, through which Panasqueira was acquired in 2005 ``.

1. Track record: built Almonty from a single Iberian mine into a multi-asset producer and pushed the Sangdong restart over the line on plan — the hard part most juniors fail. Credible operator in a niche with very few credible operators.
2. Skin in the game: ~11.91% (11.0M direct + 13.9M indirect shares) — large founder stake; bought 50,000 shares on-market March 2025 ``. Insider buying into a rip is a positive tell.
3. Capital allocation: has continuously diluted to fund Sangdong (IPO, follow-ons, the US$700M convert) — necessary for a capital-hungry mine restart, but holders have been repeatedly tapped. The US$700M 2.25% convertible due 2031 (US$83M capped call / US$50M refi / US$543M working-capital + "may include acquisitions") is cheap-coupon, equity-linked money raised at a high stock price — opportunistic and shareholder-aware, but the "acquisitions" line is a watch-item for empire-building ``.
4. Red flags: promotional CEO (heavy media, geopolitical framing, "world's most advanced mine"); GTP/Plansee is simultaneously offtake partner, financier-enabler and top-5 shareholder — a deeply intertwined related set that is strategically coherent but reduces arm's-length independence. ROE/ROIC are negative on trailing data (ramp + derivative mark), so the capital-allocation scorecard won't be readable until Sangdong cash flows mature.
5. Archetype: founder-operator with conviction, not a caretaker manager — the right archetype for a multi-decade strategic-asset build, but one whose promotional tilt must be discounted in the bull case.

Other holders signal quality: Deutsche Rohstoff AG (~7.97%) — a disciplined German resources holder; Van Eck, Fidelity institutional positions (~36% institutional total) ``.

Forensic Red Flags

Forensic lens — where could the accounting mislead?

1. The C$87.3M non-cash derivative-revaluation "loss" (FY2025) — the headline trap, but honestly disclosed. It inflates the net loss to C$161.9M purely because the share price rose (embedded-derivative/convertible mark-to-market). It is non-cash and reverses if the stock falls — but it also means future quarters of stock appreciation will keep printing GAAP losses, and the new US$700M convertible adds a much larger derivative/dilution overhang. Watch: GAAP net loss will likely stay ugly and uncorrelated to operations — judge the company on EBITDA/operating cash flow, not net income ``.
2. Price-driven revenue on falling volumes. Q1'26's +221% came with −15% volumes. The revenue line is 100% leveraged to the APT price — quality of the top line is entirely a commodity bet until Sangdong tonnes arrive ``.
3. CAD/USD presentation ambiguity across outlets (revenue in C$, raises in US$) — a real risk of double-counting/misreading; reconcile to the actual filing currency (CAD financials) before modelling.
4. Capex/ramp watch: Sangdong's full economics (AISC, sustaining capexCapital expenditureMoney spent on long-lived things — buildings, machines, servers — rather than on running costs., Phase 2 budget) are not disclosed in public sources — n/a. A high-grade deposit should be low-cost, but unconfirmed; cost overruns or ramp slippage are the live operational risk.
5. Related-party density (GTP = customer + shareholder; KfW + Plansee + Deutsche Rohstoff German cluster) — strategically aligned, but offtake-pricing fairness is hard to audit from outside.
6. Convertible dilution: ~283.7M shares + a US$700M convert + ~12.1M equity-plan capacity → real future share-count creep; per-share metrics must be modelled fully diluted ``.

Regulatory findings (required). Per regulatory/regulatory-findings.md : **Almonty has no CIK historically and `total_sec_findings: 0`** — no SEC Litigation Releases or AAERs (it was a foreign issuer not required to file; it has *since* domesticated and files 6-Ks). Non-SEC web search (`"Almonty Industries" (FTC OR DOJ OR FDA OR consent decree OR settlement OR fine OR penalty) enforcement`) surfaced **no material enforcement actions** . 10-KForm 10-KA company’s audited annual report to the US regulator. The most complete thing it publishes. Item 3 (Legal Proceedings) not fetched here (EDGAR not pulled per run constraints) — flagged as an open item to verify on the next filing-grounded pass. Net: no material regulatory or legal findings identified — verified via the regulatory-findings file (0 SEC LR/AAER) + web search as of 2026-06-20; 10-K/F-10 Item-3 review pending a filing-grounded refresh.

---

Phase D — Project & stress-test

Forward Projection (FY2026E / FY2027E / FY2028E)

Built top-down from web consensus + offtake floors; all /. Almonty reports CAD.

Anchor inputs:

• 2026E revenue ~C$747.7M, EBITDA ~C$488.1M (>50% margin) per company-sponsored research; BofA adj EBITDA ~C$597M for 2026 ``. (Spread reflects tungsten-price + ramp-timing assumptions.)
• Revenue "set to surge ~20×" as Sangdong ramps + tungsten price holds ``.
• Floor protection: GTP US$183/MTU WO₃ (no cap) + SeAH moly US$19/lb.
• Spot APT > US$3,100/mtu vs the US$183/MTU-equivalent floor → Almonty currently sells far above its floor; the floor is downside insurance, not the operating price ``.

Scenario EPS (≈283.7M shares; pre-full-convert dilution; CAD):

• Bear (~C$0.30–0.60 EPS): Sangdong Phase-1 ramp slips a few quarters; tungsten mean-reverts toward US$1,000–1,500/mtu as China partially eases; Panasqueira volumes keep fading. Revenue lands well under C$747M; GAAP still polluted by derivative marks ``.
• Base (~C$1.00–1.40 EPS): Sangdong Phase 1 at run-rate by 2H'26, tungsten elevated but off peak (US$2,000–3,000/mtu), EBITDA ~C$490–600M as guided. P/E ~13–18× on ~$19 share — the multiple compresses dramatically if this prints ``.
• Bull (~C$1.80–2.50+ EPS): tungsten holds >US$3,000 on the 2027 Pentagon ban + 15-licensee China regime; Phase 2 (2027) de-risks early; Montana adds U.S. tonnes; molybdenum kicks in. Multi-year compounding annuity ``.

The asymmetry: on trailing numbers it looks absurd (EV/Sales ~149); on 2026E it looks ordinary-to-cheap (fwd P/E ~13–18× in the base) — if the ramp and the price both hold. The bet is entirely execution × tungsten price, both of which are partly outside management's control.

Forecast NOT logged (our model create skipped — --watchlist rule; no committed base case from an unattended run). The scoreable line if promoted: "ALM FY26 EBITDA ≥ C$490M (resolves 2027-03-31), p≈0.55."

Bull vs Bear

Bull case. Almonty is the single most direct, scaled, investable Western-aligned tungsten producer at the exact moment tungsten became a national-security choke point. Stacked moat (45-yr high-grade reserve + allied jurisdiction + floored-uncapped offtakes + 126-yr operating pedigree). 2026E EBITDA ~C$490–600M turns the "expensive" multiple ordinary in a single year; Phase 2 (2027), molybdenum, and Montana extend the runwayRunwayHow long the cash lasts at the current rate of spending. It shortens the moment spending rises, which is why a figure taken from a quiet quarter flatters.; the 1 Jan 2027 Pentagon ban is a hard, dated demand catalyst with no Chinese substitute. Founder owns ~12% and is buying. What the market refuses to see (contrarian): this is not a junior miner — it's a multi-decade strategic-supply annuity with a sovereign-aligned buyer base; if tungsten stays a contested metal, the floor under demand is structural, not cyclical.

Bear case. Three ways it permanently impairs or de-rates hard:

1. China de-escalates. The entire move is China's export squeeze. A trade détente / quota relaxation collapses the tungsten price and the multiple together — the floor protects revenue but not the equity's ~$5B valuation.
2. Single-mine execution. ~Everything forward rides on Sangdong ramping on time and on cost. Ramps slip; AISC is undisclosed; Wolf Minerals (Hemerdon) is the ex-China tungsten junior that went bankrupt on exactly this ``. One bad ramp quarter re-rates the stock 30–40%.
3. Valuation/expectations. ~149× trailing sales, fwd P/E ~57, ~$5B cap on ~C$100M trailing revenue prices in flawless execution + sustained peak pricing. Any disappointment has a long way to fall; the US$700M convert adds dilution/derivative overhang.

Pre-mortem (18 months out, thesis broke): China cut a tungsten-supply deal with the U.S./allies or simply re-opened quotas; APT fell from >$3,100 toward $1,200; Sangdong Phase 1 ran a couple of quarters behind on a processing-plant snag; the stock round-tripped from ~$22 to single digits while GAAP losses (derivative marks) kept scaring generalist holders. The mine is still a fine 45-year asset — but the equity was priced for the spike, not the asset.

Multiples too high? On trailing — egregiously. On 2026E base — defensible-to-cheap. The honest answer: the multiple is a leveraged bet on two variables (ramp, tungsten price), not a mispricing to arbitrage.

Devil's Advocate (short-seller)

Dismantling the bull case.

• Revenue concentration is total: ~100% from one mature mine (Panasqueira, with declining volumes) until Sangdong proves out — and Sangdong is one asset in one country. There is no diversification behind the forward numbers.
• The whole thesis is a single exogenous variable: the China tungsten price/export policy. You are not buying a business; you are buying a high-beta, levered call on Beijing's export desk. Beijing can deflate this thesis with a single announcement — and has every incentive to manage the squeeze tactically.
• The moat is cyclical, not structural: ex-China scarcity = pricing power today. The day supply normalises, Almonty is a normal high-cost-of-capital miner with a big convertible and a promotional CEO.
• Most dangerous competitor bulls underrate: Masan/Nui Phao (Vietnam) — the existing, largest, lowest-cost ex-China producer that can expand without a 30-year-dormant-mine ramp; plus China itself flooding the market to discipline Western entrants (it has done this in rare earths repeatedly).
• Capital-allocation/governance flags: relentless dilution; a US$700M convert with a vague "may include acquisitions" mandate at a euphoric price; GTP/Plansee as customer + financier + shareholder (related-party pricing opacity); a CEO who markets like a promoter.
• Accounting optics: GAAP net loss C$161.9M; derivative marks that will keep polluting earnings; AISC undisclosed — you are trusting an unverified low-cost claim.
• What must hold for ~$19: tungsten stays elevated for years AND Sangdong ramps on time/cost AND Phase 2 + moly + Montana all land. If growth disappoints 20–30%, EV/Sales compresses from ~149 against a much smaller revenue base → a 40–60% drawdown is easily achievable without anything "going wrong" operationally — just normalisation.
• The single permanent-impairment scenario: a Sangdong technical/geotechnical failure (underground restart) coincident with a China supply re-opening — asset value intact, but equity de-rated to a single-mine European cash cow worth a fraction of $5B. Plausibility: low-but-not-trivial — and the payoff is highly asymmetric to the downside at this multiple.

Management Questions (ordered by information value)

1. What is Sangdong Phase 1's realised AISC per MTU in the first two quarters of commercial production, and how does it compare to your feasibility assumption?
2. Walk me through the monthly Sangdong Phase 1 ramp curve to nameplate (2,300 t/yr) — where are you vs plan today, and what is the gating constraint (processing recovery? underground development? grade reconciliation?)?
3. What tungsten price (APT) do you underwrite Phase 2 and the US$700M convert against — and what is your operating plan if APT mean-reverts to US$1,000–1,200/mtu?
4. The US$543M "working capital and general corporate, may include acquisitions" — what specifically, and what is your hard discipline against value-destructive M&A at this point in the cycle?
5. How should investors separate operating performance from the derivative-revaluation GAAP noise — what is the cleanest cash metric, and how large is the convert-driven mark going forward?
6. Panasqueira volumes are declining — what is its reserve life and production trajectory, and is it a melting ice cube funding Sangdong or a durable second leg?
7. Quantify the GTP/Plansee relationship: how is offtake pricing above the floor set, and how do you manage the conflict of a customer who is also a major shareholder and financier?
8. What is the realistic timeline and capex for Phase 2, the tungsten-oxide facility, and the molybdenum deposit — the "Korean Trinity" — and what de-risks the 2027 date?
9. What volume of the U.S. defense tungsten-oxide offtake is contracted, at what economics, and how does the 1 Jan 2027 Pentagon ban convert into firm Almonty tonnage?
10. How exposed are you to a China de-escalation — what share of your forward EBITDA survives a normalisation of the APT price to pre-2025 levels?
11. Montana/Gentung: real production asset on a defined timeline, or optionality/narrative? What capital does it need?
12. Post-convert, what is the fully-diluted share count and net debt, and what is your through-cycle capital-allocation priority (debt paydown vs growth vs returns)?
13. What is the realistic substitution / thrifting risk in carbide and munitions if tungsten stays >US$3,000/mtu for years?
14. What is your geotechnical risk profile restarting a 30-year-dormant underground mine, and what contingency exists for a Wolf-Minerals-style cost/recovery failure?
15. What insider buying/selling should we expect from you and the board over the next 12 months at these levels?

---